SUMO pathway components as possible cancer biomarkers

Future Oncology

Volumn 11, Issue 11, 2015, Pages 1599-1610

  Mattoscio, Domenico ^a   Chiocca, Susanna ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

biomarkers; cancer; SAE1 2; SUMO; SUMO ligases; SUMO proteases; Ubc9

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; LIGASE; MESSENGER RNA; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; SUMO PROTEIN; UBIQUITIN CONJUGATING ENZYME E1; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E3; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CHAPERONE; NUCLEOPORIN; PEPTIDE HYDROLASE; PIAS1 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT; RAN-BINDING PROTEIN 2; SAE1 PROTEIN, HUMAN; SUMO1 PROTEIN, HUMAN; TUMOR MARKER; UBA2 PROTEIN, HUMAN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN-CONJUGATING ENZYME UBC9;

APOPTOSIS; BINDING SITE; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; CONJUGATION; ENZYME ACTIVITY; GENETIC CODE; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NUCLEAR PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RING FINGER MOTIF; SUMOYLATION; UBIQUITINATION; ANIMAL; GENETICS; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS; NUCLEAR PORE COMPLEX PROTEINS; PEPTIDE HYDROLASES; PROTEIN INHIBITORS OF ACTIVATED STAT; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMO-1 PROTEIN; SUMOYLATION; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84930607429     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.41     Document Type: Review

References (109)

1. Hay RT. SUMO: a history of modification. Mol. Cell 18(1), 1-12 (2005).
2. Sarge KD, Park-Sarge OK. Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 34(4), 200-205 (2009).
3. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11(12), 861-871 (2010).
4. Matunis MJ, Coutavas E, Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 135(6 Pt 1), 1457-1470 (1996).
5. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88(1), 97-107 (1997).
6. Citro S, Chiocca S. Sumo paralogs: redundancy and divergencies. Front. Biosci. (Schol. Ed.) 5, 544-553 (2013).
7. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275(9), 6252-6258 (2000).
8. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279(26), 27233-27238 (2004).
9. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem. Biophys. Res. Commun. 337(2), 517-520 (2005).
10. Wei W, Yang P, Pang J et al. A stressdependent SUMO4 sumoylation of its substrate proteins. Biochem. Biophys. Res. Commun. 375(3), 454-459 (2008).
11. Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276(16), 12654-12659 (2001).
12. Tatham MH, Jaffray E, Vaughan OA et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/ SAE2 and Ubc9. J. Biol. Chem. 276(38), 35368-35374 (2001).
13. Hay RT. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 17(8), 370-376 (2007).
14. Desterro JM, Rodriguez MS, Kemp GD, Hay RT. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274(15), 10618-10624 (1999).
15. Johnson ES, Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 272(43), 26799-26802 (1997).
16. Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108(3), 345-356 (2002).
17. Hochstrasser M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107(1), 5-8 (2001).
18. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol. Life Sci. 66(18), 3029-3041 (2009).
19. Potts PR, Yu H. Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Mol. Cell Biol. 25(16), 7021-7032 (2005).
20. Yunus AA, Lima CD. Structure of the Siz/PIAS SUMO E3 ligase Siz1 and determinants required for SUMO modification of PCNA. Mol. Cell 35(5), 669-682 (2009).
21. Werner A, Flotho A, Melchior F. The RanBP2/RanGAP1∗SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol. Cell 46(3), 287-298 (2012).
22. Reverter D, Lima CD. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435(7042), 687-692 (2005).
23. Kagey MH, Melhuish TA, Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 113(1), 127-137 (2003).
24. Yang SH, Sharrocks AD. The SUMO E3 ligase activity of Pc2 is coordinated through a SUMO interaction motif. Mol. Cell Biol. 30(9), 2193-2205 (2010).
25. Liang Q, Deng H, Li X et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J. Immunol. 187(9), 4754-4763 (2011).
26. Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene 30(9), 1108-1116 (2011).
27. Weger S, Hammer E, Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 579(22), 5007-5012 (2005).
28. Oh Y, Chung KC. UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131. J. Biol. Chem. 288(13), 9102-9111 (2013).
29. Ikeuchi Y, Dadakhujaev S, Chandhoke AS et al. TIF1gamma protein regulates epithelial-mesenchymal transition by operating as a small ubiquitin-like modifier (SUMO) E3 ligase for the transcriptional regulator SnoN1. J. Biol. Chem. 289(36), 25067-25078 (2014).
30. Gregoire S, Yang XJ. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol. Cell Biol. 25(6), 2273-2287 (2005).
31. Gao C, Ho CC, Reineke E et al. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Mol. Cell Biol. 28(18), 5658-5667 (2008).
32. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324(5932), 1327-1330 (2009).
33. Morita Y, Kanei-Ishii C, Nomura T, Ishii S. TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Mol. Biol. Cell 16(11), 5433-5444 (2005).
34. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO proteases. Nat. Rev. Mol. Cell Biol. 13(12), 755-766 (2012).
35. Shin EJ, Shin HM, Nam E et al. DeSUMOylating isopeptidase. a second class of SUMO protease. EMBO Rep. 13(4), 339-346 (2012).
36. Schulz S, Chachami G, Kozaczkiewicz L et al. Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMBO Rep. 13(10), 930-938 (2012).
37. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 428(2), 133-145 (2010).
38. Kerscher O. SUMO junction-what?s your function? New insights through SUMOinteracting motifs. EMBO Rep. 8(6), 550-555 (2007).
39. Seeler JS, Dejean A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4(9), 690-699 (2003).
40. Luo J, Emanuele MJ, Li D et al. A genomewide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5), 835-848 (2009).
41. Kessler JD, Kahle KT, Sun T et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335(6066), 348-353 (2012).
42. Mo YY, Moschos SJ. Targeting Ubc9 for cancer therapy. Expert Opin. Ther. Targets 9(6), 1203-1216 (2005).
43. Tomasi ML, Tomasi I, Ramani K et al. S-adenosyl methionine regulates ubiquitinconjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers. Hepatology 56(3), 982-993 (2012).
44. Alshareeda AT, Negm OH, Green AR et al. SUMOylation proteins in breast cancer. Breast Cancer Res. Treat. 144(3), 519-530 (2014).
45. Geletu M, Balkhi MY, Peer Zada AA et al. Target proteins of C/EBPalphap30 in AML. C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9. Blood 110(9), 3301-3309 (2007).
46. Moschos SJ, Jukic DM, Athanassiou C et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum. Pathol. 41(9), 1286-1298 (2010).
47. Moschos SJ, Smith AP, Mandic M et al. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes. identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene 26(29), 4216-4225 (2007).
48. McDoniels-Silvers AL, Stoner GD, Lubet RA, You M. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 4(2), 141-150 (2002).
49. Wu F, Zhu S, Ding Y, Beck WT, Mo YY. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin. Cancer Res. 15(5), 1550-1557 (2009).
50. Li H, Niu H, Peng Y, Wang J, He P. Ubc9 promotes invasion and metastasis of lung cancer cells. Oncol. Rep. 29(4), 1588-1594 (2013).
51. Han JY, Lee GK, Yoo SY et al. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics J. 10(2), 86-93 (2010).
52. Ronen O, Malone JP, Kay P et al. Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck. Head Neck 31(7), 845-855 (2009).
53. Zhao Z, Tan X, Zhao A et al. microRNA-214-mediated UBC9 expression in glioma. BMB Rep. 45(11), 641-646 (2012).
54. Wang S, Jiao B, Geng S, Ma S, Liang Z, Lu S. Combined aberrant expression of microRNA-214 and UBC9 is an independent unfavorable prognostic factor for patients with gliomas. Med. Oncol. 31(1), 767 (2014).
55. Qin Y, Xu J, Aysola K et al. Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins. J. Cell Physiol. 226(12), 3355-3367 (2011).
56. Chen SF, Gong C, Luo M, Yao HR, Zeng YJ, Su FX. Ubc9 expression predicts chemoresistance in breast cancer. Chin. J. Cancer 30(9), 638-644 (2011).
57. Agboola AO, Musa AA, Ayoade BA et al. Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women. Pathol. Res. Pract. 210(1), 10-17 (2014).
58. Dunnebier T, Bermejo JL, Haas S et al. Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int. J. Cancer 125(3), 596-602 (2009).
59. Wozniak K, Krupa R, Synowiec E, Morawiec Z. Polymorphism of UBC9 gene encoding the SUMO-E2-conjugating enzyme and breast cancer risk. Pathol. Oncol. Res. 20(1), 67-72 (2014).
60. Yang W, Wang L, Roehn G et al. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci. 104(1), 70-77 (2013).
61. Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. J. Cancer Res. Clin. Oncol. 135(9), 1287-1291 (2009).
62. Chen P, Zhao D, Sun Y, Huang L, Zhang S, Yuan Y. Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis. Oncol. Rep. 28(6), 2149-2155 (2012).
63. Wei J, Costa C, Ding Y et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J. Natl Cancer Inst. 103(20), 1552-1556 (2011).
64. Hoefer J, Schafer G, Klocker H et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am. J. Pathol. 180(5), 2097-2107 (2012).
65. Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol. Rep. 11(6), 1319-1324 (2004).
66. Li H, Gao H, Bijukchhe SM, Wang Y, Li T. PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer. Med. Hypotheses 81(6), 1151-1154 (2013).
67. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell Biochem. 110(2), 447-456 (2010).
68. Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R, Dowlati A. Protein inhibitor of activated STAT3 expression in lung cancer. Mol. Oncol. 5(3), 256-264 (2011).
69. Liu LM, Yan MG, Yang DH, Sun WW, Zhang JX. PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues. Clin. Res. Hepatol. Gastroenterol. 35(5), 393-398 (2011).
70. Agboola A, Musa A, Banjo A et al. PIASgamma expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. J. Clin. Pathol. 67(4), 301-306 (2014).
71. Ueda M, Ota J, Yamashita Y et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br. J. Haematol. 123(2), 288-296 (2003).
72. Felix RS, Colleoni GW, Caballero OL et al. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Lett. 278(1), 41-48 (2009).
73. Horio Y, Osada H, Shimizu J, Ogawa S, Hida T, Sekido Y. Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines. Cancer Chemother. Pharmacol. 66(2), 237-243 (2010).
74. Chen ST, Lee JC. An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. Hum. Pathol. 39(12), 1854-1858 (2008).
75. Butrynski JE, D?adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363(18), 1727-1733 (2010).
76. Maesako Y, Izumi K, Okamori S et al. inv(2) (p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. Int. J. Hematol. 99(2), 202-207 (2014).
77. Lim JH, Jang S, Park CJ et al. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. Cancer Genet. 207(1-2), 40-45 (2014). ? Report of a case of RANBP2-ALK fusion in myeloproliferative disorders.
78. Gervais C, Dano L, Perrusson N et al. A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358 in a myeloproliferative/myelodysplastic neoplasm. Leukemia 27(5), 1186-1188 (2013).
79. Wang B, Tang J, Liao D et al. Chromobox homolog 4 is correlated with prognosis and tumor cell growth in hepatocellular carcinoma. Ann. Surg. Oncol. 20(Suppl. 3), S684-S692 (2013).
80. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93(10), 3167-3215 (1999).
81. Kato T, Shimono Y, Hasegawa M et al. Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 69(8), 3597-3604 (2009).
82. Tsukamoto H, Kato T, Enomoto A et al. Expression of Ret finger protein correlates with outcomes in endometrial cancer. Cancer Sci. 100(10), 1895-1901 (2009).
83. Horio M, Kato T, Mii S et al. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer. Cancer Med. 1(2), 218-229 (2012).
84. Cheng J, Bawa T, Lee P, Gong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia 8(8), 667-676 (2006).
85. Wang Q, Xia N, Li T et al. SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene 32(19), 2493-2498 (2013).
86. Li T, Huang S, Dong M, Gui Y, Wu D. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy. Urol. Oncol. 31(8), 1539-1545 (2013).
87. Ma C, Wu B, Huang X et al. SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9. Tumour Biol. 35(12), 12729-12735 (2014).
88. Tan MY, Mu XY, Liu B et al. SUMO-specific protease 2 suppresses cell migration and invasion through inhibiting the expression of MMP13 in bladder cancer cells. Cell Physiol. Biochem. 32(3), 542-548 (2013).
89. Shen HJ, Zhu HY, Yang C, Ji F. SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac. J. Cancer Prev. 13(8), 3583-3587 (2012).
90. Han Y, Huang C, Sun X et al. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J. Biol. Chem. 285(17), 12906-12915 (2010).
91. Sun Z, Hu S, Luo Q, Ye D, Hu D, Chen F. Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol. Rep. 29(5), 1701-1706 (2013).
92. Ding X, Sun J, Wang L et al. Overexpression of SENP5 in oral squamous cell carcinoma and its association with differentiation. Oncol. Rep. 20(5), 1041-1045 (2008).
93. Cashman R, Cohen H, Ben-Hamo R, Zilberberg A, Efroni S. SENP5 mediates breast cancer invasion via a TGFbetaRI SUMOylation cascade. Oncotarget 5(4), 1071-1082 (2014).
94. Mooney SM, Grande JP, Salisbury JL, Janknecht R. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry 49(1), 1-10 (2010).
95. Bawa-Khalfe T, Lu LS, Zuo Y et al. Differential expression of SUMO-specific protease 7 variants regulates epithelialmesenchymal transition. Proc. Natl Acad. Sci. USA 109(43), 17466-17471 (2012).
96. Bermejo JL, Kabisch M, Dunnebier T et al. Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases. Int. J. Cancer 133(2), 362-372 (2013).
97. Guo WH, Yuan LH, Xiao ZH, Liu D, Zhang JX. Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma. J. Cancer Res. Clin. Oncol. 137(3), 533-541 (2011).
98. Oliveira Alves MG, Da Mota Delgado A, Balducci I, Carvalho YR, Cavalcante AS, Almeida JD. Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer. Arch. Dermatol. Res. 306(9), 837-841 (2014).
99. Katayama A, Ogino T, Bandoh N et al. Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma. possible involvement in tumor proliferation and prognosis. Int. J. Oncol. 31(3), 517-524 (2007).
100. Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT. A role for Ubc9 in tumorigenesis. Oncogene 24(16), 2677-2683 (2005).
101. Lu Z, Wu H, Mo YY. Regulation of bcl-2 expression by Ubc9. Exp. Cell Res. 312(10), 1865-1875 (2006).
102. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29(12), 1763-1772 (2010).
103. Xu J, Watkins T, Reddy A, Reddy ES, Rao VN. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMOdependent/ independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. Int. J. Oncol. 34(4), 939-949 (2009).
104. Dunnebier T, Bermejo JL, Haas S et al. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk. Breast Cancer Res. Treat. 121(1), 185-194 (2010).
105. Gylfe AE, Kondelin J, Turunen M et al. Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. Gastroenterology 145(3), 540-543.e522 (2013).
106. Barreca A, Lasorsa E, Riera L et al. Anaplastic lymphoma kinase in human cancer. J. Mol. Endocrinol. 47(1), R11-23 (2011).
107. Hatakeyama S. TRIM proteins and cancer. Nat. Rev. Cancer 11(11), 792-804 (2011).
108. Bettermann K, Benesch M, Weis S, Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett. 316(2), 113-125 (2012).
109. Mattoscio D, Casadio C, Fumagalli M, Sideri M, Chiocca S. The SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections. eCancer 9, 534 (2015).